Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Exclusion Criteria

• •Positive test at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody
• •History of any other clinically significant chronic liver disease
• •History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions consistent with decompensated liver disease
• •Positive results on urine screen for drugs of abuse test at Screening (unless used as medical treatment, e.g., with a prescription)
• •History of alcohol/drug abuse or dependence within 6 months of the study start (unless participating in a controlled rehabilitation program)
• •Screening ECG corrected QT interval value greater than 450 ms and/or clinically significant ECG findings
• •A personal or family history of Torsade de Pointes findings
• •Pregnant or nursing women
• •Males with a female partner who is pregnant
• •Abnormal hematological and biochemical parameters as specified in the protocol
• •History of major organ transplantation with an existing functional graft
• •Thyroid dysfunction not adequately controlled
• •Subjects with a history of suicide attempt or hospitalization for depression in the past 5 years and/or any current (within 6 months) severe or poorly controlled psychiatric disorder
• •History or current evidence of immunologic disorder; pulmonary, cardiac, or pulmonary disease; seizure disorder; cancer or history of malignancy that in the opinion of the investigator makes the subject unsuitable for the study
• •Participation in a clinical study with an investigational drug, biologic, or device within 3 months prior to first dose administration